Trevi Therapeutics Inc (TRVI)

NASDAQ:TRVI

TRVI

Trevi Therapeutics

RESEARCH TOOLSreports

Trevi Therapeutics (TRVI) Stock Forecast & Price Target

Compare

588 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

TRVI Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Trevi

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

TRVI Stock 12 Month Forecast

Average Price Target

$22.00

▲(63.33% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Trevi Therapeutics in the last 3 months. The average price target is $22.00 with a high forecast of $25.00 and a low forecast of $18.00. The average price target represents a 63.33% change from the last price of $13.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","8":"$8","14":"$14","20":"$20","26":"$26"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$22.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,8,14,20,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.57,13.526153846153846,14.482307692307693,15.438461538461539,16.394615384615385,17.35076923076923,18.306923076923077,19.263076923076923,20.21923076923077,21.175384615384615,22.13153846153846,23.087692307692308,24.043846153846154,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.57,13.295384615384616,14.02076923076923,14.746153846153847,15.471538461538461,16.196923076923078,16.922307692307694,17.64769230769231,18.373076923076923,19.09846153846154,19.823846153846155,20.549230769230768,21.274615384615387,{"y":22,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.57,12.987692307692308,13.405384615384616,13.823076923076924,14.240769230769232,14.65846153846154,15.076153846153847,15.493846153846153,15.911538461538463,16.32923076923077,16.74692307692308,17.164615384615384,17.582307692307694,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.94,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.32,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.27,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.3,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.52,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.96,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.57,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$25.00

Average Price Target$22.00

Lowest Price Target$18.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Debanjana Chatterjee

JonesTrading

$25→$24

Buy

78.17%

Upside

Reiterated

03/19/26

Analysts Conflicted on These Healthcare Names: Trevi Therapeutics (NASDAQ: TRVI), Annexon Biosciences (NASDAQ: ANNX) and Medtronic (NYSE: MDT)

Annabel Samimy

Stifel Nicolaus

$18

Buy

33.63%

Upside

Reiterated

03/18/26

Trevi Therapeutics (TRVI) Receives a Buy from Stifel Nicolaus

Serge Belanger

Needham

$24

Buy

78.17%

Upside

Assigned

03/18/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: SanBio Co (Other OTC: SNBIF) and Trevi Therapeutics (NASDAQ: TRVI)

Leland Gershell

Oppenheimer

$24

Buy

78.17%

Upside

Reiterated

03/18/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: 4D Molecular Therapeutics (NASDAQ: FDMT), Protagonist Therapeutics (NASDAQ: PTGX) and Trevi Therapeutics (NASDAQ: TRVI)

Judah Frommer

Morgan Stanley

$19→$18

Buy

33.63%

Upside

Reiterated

03/18/26

Trevi Therapeutics price target lowered to $18 from $19 at Morgan StanleyTrevi Therapeutics price target lowered to $18 from $19 at Morgan Stanley

Brandon Folkes

H.C. Wainwright

$6→$21

Buy

55.90%

Upside

Reiterated

03/18/26

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (NASDAQ: TRVI) and Assertio Therapeutics (NASDAQ: ASRT)

Joshua Schimmer

Cantor Fitzgerald

$25

Buy

85.60%

Upside

Reiterated

03/17/26

Cantor Fitzgerald Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)

Roanna Ruiz

Leerink Partners

$13→$16

Buy

18.78%

Upside

Reiterated

11/18/25

Trevi Therapeutics price target raised to $16 from $13 at LeerinkTrevi Therapeutics price target raised to $16 from $13 at Leerink

Kaveri Pohlman

Clear Street

$11→$21

Buy

55.90%

Upside

Reiterated

11/14/25

Trevi Therapeutics (TRVI) Receives a Buy from Clear Street

Faisal Khurshid

Jefferies

―

Buy

―

Reiterated

09/29/25

Trevi Therapeutics (TRVI) Receives a Buy from Leerink Partners

Mayank Mamtani

B. Riley Securities

$20→$16

Buy

18.78%

Upside

Reiterated

08/14/25

B.Riley Financial Sticks to Their Buy Rating for Trevi Therapeutics (TRVI)

Ryan Deschner

Raymond James

$29→$27

Buy

100.45%

Upside

Reiterated

08/08/25

Trevi Therapeutics price target lowered to $27 from $29 at Raymond JamesTrevi Therapeutics price target lowered to $27 from $29 at Raymond James

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Debanjana Chatterjee

JonesTrading

$25→$24

Buy

78.17%

Upside

Reiterated

03/19/26

Analysts Conflicted on These Healthcare Names: Trevi Therapeutics (NASDAQ: TRVI), Annexon Biosciences (NASDAQ: ANNX) and Medtronic (NYSE: MDT)

Annabel Samimy

Stifel Nicolaus

$18

Buy

33.63%

Upside

Reiterated

03/18/26

Trevi Therapeutics (TRVI) Receives a Buy from Stifel Nicolaus

Serge Belanger

Needham

$24

Buy

78.17%

Upside

Assigned

03/18/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: SanBio Co (Other OTC: SNBIF) and Trevi Therapeutics (NASDAQ: TRVI)

Leland Gershell

Oppenheimer

$24

Buy

78.17%

Upside

Reiterated

03/18/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: 4D Molecular Therapeutics (NASDAQ: FDMT), Protagonist Therapeutics (NASDAQ: PTGX) and Trevi Therapeutics (NASDAQ: TRVI)

Judah Frommer

Morgan Stanley

$19→$18

Buy

33.63%

Upside

Reiterated

03/18/26

Trevi Therapeutics price target lowered to $18 from $19 at Morgan StanleyTrevi Therapeutics price target lowered to $18 from $19 at Morgan Stanley

Brandon Folkes

H.C. Wainwright

$6→$21

Buy

55.90%

Upside

Reiterated

03/18/26

Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (NASDAQ: TRVI) and Assertio Therapeutics (NASDAQ: ASRT)

Joshua Schimmer

Cantor Fitzgerald

$25

Buy

85.60%

Upside

Reiterated

03/17/26

Cantor Fitzgerald Sticks to Its Buy Rating for Trevi Therapeutics (TRVI)

Roanna Ruiz

Leerink Partners

$13→$16

Buy

18.78%

Upside

Reiterated

11/18/25

Trevi Therapeutics price target raised to $16 from $13 at LeerinkTrevi Therapeutics price target raised to $16 from $13 at Leerink

Kaveri Pohlman

Clear Street

$11→$21

Buy

55.90%

Upside

Reiterated

11/14/25

Trevi Therapeutics (TRVI) Receives a Buy from Clear Street

Faisal Khurshid

Jefferies

―

Buy

―

Reiterated

09/29/25

Trevi Therapeutics (TRVI) Receives a Buy from Leerink Partners

Mayank Mamtani

B. Riley Securities

$20→$16

Buy

18.78%

Upside

Reiterated

08/14/25

B.Riley Financial Sticks to Their Buy Rating for Trevi Therapeutics (TRVI)

Ryan Deschner

Raymond James

$29→$27

Buy

100.45%

Upside

Reiterated

08/08/25

Trevi Therapeutics price target lowered to $27 from $29 at Raymond JamesTrevi Therapeutics price target lowered to $27 from $29 at Raymond James

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Trevi Therapeutics

3 Months

xxx

Success Rate

10/12 ratings generated profit

Average Return

+28.72%

reiterated a xxx

rating 8 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +28.72% per trade.

1 Year

Faisal KhurshidJefferies

Success Rate

11/11 ratings generated profit

Average Return

+148.39%

reiterated a buy rating 6 months ago

Copying Faisal Khurshid's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +148.39% per trade.

2 Years

xxx

Success Rate

18/18 ratings generated profit

Average Return

+234.72%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +234.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TRVI Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, TRVI has received 15 Buy Ratings, 31 Hold Ratings, and 0 Sell Ratings. TRVI average Analyst price target in the past 3 months is 22.00.

Each month's total comprises the sum of three months' worth of ratings.

TRVI Financial Forecast

TRVI Earnings Forecast

Next quarter’s earnings estimate for TRVI is -$0.08 with a range of -$0.11 to -$0.05. The previous quarter’s EPS was -$0.06. TRVI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year TRVI has Performed in-line its overall industry.

No data currently available

TRVI Sales Forecast

Next quarter’s sales forecast for TRVI is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TRVI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year TRVI has Performed in-line its overall industry.

TRVI Stock Forecast FAQ

What is TRVI’s average 12-month price target, according to analysts?

Based on analyst ratings, Trevi Therapeutics Inc’s 12-month average price target is 22.00.

What is TRVI’s upside potential, based on the analysts’ average price target?

Trevi Therapeutics Inc has 63.33% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TRVI a Buy, Sell or Hold?

Trevi Therapeutics Inc has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Trevi Therapeutics Inc’s price target?

The average price target for Trevi Therapeutics Inc is 22.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $25.00 ,the lowest forecast is $18.00. The average price target represents 63.33% Increase from the current price of $13.47.

What do analysts say about Trevi Therapeutics Inc?

Trevi Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of TRVI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Trevi Therapeutics (TRVI) Stock Forecast & Price Target

TRVI Analyst Ratings

TRVI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Trevi Therapeutics

TRVI Analyst Recommendation Trends

TRVI Financial Forecast

TRVI Earnings Forecast

TRVI Sales Forecast

TRVI Stock Forecast FAQ

Detailed List of Analyst Forecasts